Articles On Noxopharm (ASX:NOX)

Australian clinical-stage drug development company, Noxopharm Limited (ASX: NOX), has provided commentary on clinical data to be released to a cancer conference in November. Noxopharm believes that the data adds to the growing body of evide...

Noxopharm (ASX:NOX) has provided further information on the upcoming release of clinical data concerning its lead drug candidate, Veyonda, saying it "now sees an important and exciting story emerging".

Noxopharm (ASX: NOX) is in the process of making Veyonda®, which is a drug that boost the effectiveness of two forms of radiation therapy in prostate cancer with the aim of relieving pain, decreasing the activity of the cancer and extending...

Noxopharm (ASX:NOX) has announced that scientific abstracts on interim data relating to its DARRT-1 prostate cancer treatment study have been accepted for inclusion in two major oncology conferences.

Noxopharm Limited is a clinical stage drug development company that is currently investing its lead anti- cancer drug. Join Our Discussion Start discussion with value Investors for ASX Stock Market Investment and Opinion. 6 Cannabis S...

Noxopharm (ASX:NOX) has provided an update on results from a series of proof-of-principle experiments in mice that are exploring the interaction between Veyonda and radiotherapy in a novel treatment regimen known as DARRT.

Noxopharm Limited (ASX: NOX) has recently released its quarterly report for the three months ended 30 June 2019, covering updates from both Noxopharm and its majority-owned subsidiary, Nyrada Inc. Let us travel through the chief development...

Sydney-based company Noxopharm is developing a new approach to cancer treatment that is designed to convert 'cold' tumours to 'hot' so they can be recognised by the immune system.

Noxopharm Limited (ASX: NOX) plans to accelerate the development of Veyonda® on the foundation of its encouraging interim results from both its DARRT-1 and LuPIN studies. The most recent  data supports the company’s belief that its immuno-o...

Medibio (ASX: MEB) has gained 24 per cent this morning after announcing an integration partnership with digital corporate wellness solution WellteQ. Medibio’s “ilumen” digital mental well-being assessment will be integrated into WellteQ’s s...

Noxopharm Limited (ASX: NOX) is a clinical stage drug development company based in Australia. The company, currently, is focused on investigating the potential of its drug candidate Veyonda® with the vision to launch it as a one big solutio...

Noxopharm Limited (ASX: NOX) has released July 2019 edition of its Newsletter called ‘Versatility’. The clinical-stage drug development company, Noxopharm reports on the progress of its lead anti-cancer drug candidate Veyonda® achieved over...

Clinical stage drug development company, Noxopharm Limited (ASX: NOX) aims to bring hope to cancer patients who have reached the end of their treatment journey and have no standard treatment options remaining, except palliative therapy for...

In the world of cancer, one billion-dollar molecule that has been making a big noise for its potential to extend life in men with the late-stage prostate cancer, concerns an experimental radioactive drug called Lutetium-177 (177Lu) labelled...

The big noise internationally in the treatment of prostate cancer is an experimental drug called 177Lu-PSMA-617. It is what is called a radiopharmaceutical, meaning that it is a radioactive drug that is injected intravenously. It is a way o...

Clinical-stage drug development company, Noxopharm Limited (ASX: NOX) has released its updated corporate presentation for June 2019. The company, with offices in Sydney, New York and Hong Kong, is developing its leading drug candidate, Veyo...

07 Jun 2019 - Noxopharm (ASX:NOX) has seen its majority-owned US subsidiary company, Nyrada receive a cash rebate of over $486,000 under the Australian Government’s R&D Tax Incenti…